Background
Myotonic dystrophy type 1 (DM1), also known as Steinert’s disease, is one of the most common forms of adult-onset muscular dystrophy, with a prevalence of 9.27 per 100,000 [
1]. DM1 is caused by abnormal expansion of CTG repeats in the 3
’ untranslated region of the myotonic dystrophy protein kinase (DMPK) gene on chromosome 19 [
2]. Unaffected individuals harbor 5–35 copies of CTG repeats, whereas DM1 patients carry 50 or more copies [
3]. The CUG repeats transcribed from the abnormally expanded CTG repeats sequestrate muscleblind-like protein 1 (MBNL1), leading to the downregulation of free MBNL1 [
4]. The limited MBNL1 availability leads to the aberrant regulation of alternative splicing of hundreds of genes, causing various clinical manifestations such as progressive muscle wasting, myotonia, insulin resistance, cardiac arrhythmia, cataracts, and intellectual deficits [
5].
Recently, some therapeutic approaches have been designed for DM1 [
6,
7]. There is numerous evidence that MBNL1 functions are the limiting factors in DM1, and the upregulation of MBNL1 expression is one of the promising therapies for DM1. In animal experiments,
Mbnl1 knockout mice recapitulate the main clinical symptoms for DM1, such as myotonia, aberrant splicing, cataracts, cardiac dysfunctions, and progressive skeletal muscle weakness [
8,
9]. In complementary gain-of-function experiments, the overexpression of
Mbnl1 in skeletal muscle, using a recombinant adeno-associated viral vector in a murine model expressing 250 CTG repeats (HSA
LR mice), rescued myotonia, hyperexcitability, and aberrant splicing [
5,
10]. MBNL1 upregulation in DM1 mice and DM1
drosophila is well tolerated without obvious side effects, and rescues several symptoms, such as myotonia, myopathy, and mis-splicing events [
11,
12].
Vitamin D is a steroid hormone, of which approximately 80% is produced in the skin [
13]. In the skin, 7-dehydrocholesterol is transferred into pre-vitamin D3 and then vitamin D3 under the action of ultraviolet-B radiation. Vitamin D3 is further converted to 25-hydroxyvitamin D [25(OH)D] in the liver and 1,25-hydroxyvitamin D (1,25(OH)2D, also called calcitriol), an active form of vitamin D3, in the kidney [
14]. Previous studies found that DM1 patients have a reduction of circulating 25(OH)D, which correlates with the severity of the disease, suggesting that vitamin D supplement may alleviate some symptoms of DM1 patients [
15,
16].
In this study, we first identified that calcitriol increases MBNL1 in C2C12 mouse myoblasts. Next, we confirmed that calcitriol improves muscle strength in HSALR mice model for DM1. Calcitriol enhances MBNL1 expression and corrects aberrant splicing in skeletal muscle of HSALR mice. Besides, calcitriol reduces the number of central nuclei, and improves muscle histopathology in HSALR mice. In addition, we identified that calcitriol upregulates MBNL1 expression via activating the promoter of Mbnl1 in C2C12 myogenic cells. Our study suggests that calcitriol is a promising pharmacological strategy for DM1.
Methods
C2C12 cell culture and drug treatment
C2C12 myoblasts (National Collection of Authenticated Cell Cultures, serial: SCSP-505) were cultured in Dulbecco’s modified Eagle’s medium (DMEM, Gibco, Cat. C12430500BT) supplemented with 10% (v/v) fetal bovine serum (FBS, Procell, Cat. 164210-50) and incubated at 37 °C with 5% CO2. Different concentrations of calcitriol (MCE, HY-10,002) or ergocalciferol (Aladdin, E106318) were added into the culture medium of C2C12 myoblasts with 50–60% confluency for 24 h before analysis. To examine the effect of calcitriol or ergocalciferol in differentiated C2C12 myotubes, C2C12 myoblasts were grown to 95% confluency in DMEM with 10% FBS, and then changed into the differentiation medium containing 2% horse serum (HS) (Biological Industries, Cat. 04-004-1B) and various concentrations of calcitriol or ergocalciferol in DMEM for five days before analysis.
Administration of calcitriol to DM1 mouse model
All mouse studies were approved by the Department of Laboratory Animals of Central South University, and were performed in accordance with the relevant guidelines. HSA
LR transgenic mice, which express approximately 250 untranslated CUG repeats driven by a muscle-specific promoter, were bought from The Jackson Laboratory, USA (Strain #:032031) [
17]. The wild-type FVB/N (WT) mice that have the same genetic background were bought from the Department of Laboratory Animals of Central South University. Mice were divided into three groups: (1) untreated WT mice, (2) untreated HSA
LR mice, and (3) calcitriol treated HSA
LR mice. At 12 weeks after birth, mice started to take 0.9% normal saline or 1 µg/kg/day of calcitriol, which is a physiological dose widely used in mouse experiment [
18,
19], by intraperitoneal injection for 12 weeks before sacrifice.
Blood routine examination and vitamin D level analysis
After treated with or without calcitriol for 12 weeks, blood of the mice was collected from the angular veins and transferred into a blood collection tube containing EDTA to prevent blood clotting. Blood routine examination and cell classifications were analyzed using a Sysmex Hematology Analyzer (XN-1000-B1, Dewei, China) followed with manufacturer’s instructions. Vitamin D levels were determined using Mouse VD ELISA Kit from Shanghai ZCIBIO technology Co.,Ltd, (Cat. ZC-38,755), according to the manufacturer’s instructions.
Rotarod test, grip of strength, and inverted mesh hanging test
For the rotarod test, the angular speed was accelerated from 0 to 40 rpm in 90 s with a 30 min maximum trail time (ZF44-YLS-4D, M407469). Mice were given two trials per week and the average endurance time of two trails for each animal was calculated. Mice with impaired muscle strength fell off quickly. The apparatus was cleaned between each trial to avoid odor interference.
The peak grip force was measured using a grip strength meter (YR92-YLS-13 A, M281330). Mice that grasp a wire mesh with the forelimbs and hindlimbs were pulled horizontally by their tails until they lost their grip. Measurements were performed twice and the average strength for each mouse was calculated.
Fatigability of limbs was tested for with the inverted grid hanging test [
20]. Mice were placed on the center of an invertible 40×40 cm wire grid, mounted 60 cm above a padded surface. The time was recorded from the mice hang on to drop off. Each mouse was tested twice. The average hanging times were calculated for each mouse.
Gene expression analysis and splicing analysis
RNA extraction from the tibialis anterior (TA) muscle of mouse was performed as described previously with minor modifications [
21]. Tissues were mashed by High Speed Tissue Homogenizer (Servicebio, KZ-II) in the lysis buffer from the FastPure Cell/Tissue Total RNA Isolation Kit (Vazyme, Cat. RC101-01). Total RNA from the tissues and the cultured cells was extracted by the kit according to the manufacturer’s instructions. RNA was reverse-transcribed into cDNA using RevertAid Master Mix (Thermo Fisher, Cat. M1631).
Real-time RT-PCR was performed with the QuantStudio (Thermo Fisher Scientific) using the NovoStart® SYBR qPCR SuperMix Plus (Novoprotein, Cat. E096). Gene expression levels were normalized by that of glyceraldehyde-3-phosphate dehydrogenase (
Gapdh). All real-time RT-PCR experiments were performed in duplicate. For splicing analysis, PCR amplifications were performed using 2×Taq Plus Master Mix II (Vazyme, Cat. P213) for 35 cycles. The primer sequences used for PCR are shown in Additional file
1: Table S1. The intensities of RT-PCR-amplified spliced products were quantified with the ImageJ program (
http://imagej.nih.gov/ij/). We then estimated the ratio of exon inclusion by dividing the signal intensity of the upper band by the sum of signal intensities of two bands.
Western blot and immunodecoration
Proteins from tissues and cultured cells were extracted by the lysis buffer [20 mM Tris/HCl pH 7.4, 50 mM NaCl, 10% (w/v) Glycerol, 0.1 mM EDTA, 2% SDS] supplemented with cOmplete protease inhibitor (Roche) and 1 mM PMSF. The protein concentration was quantified using Pierce 660 nm Protein Assay Reagent (Thermo Scientific, Cat. 23,225). Proteins were separated by SDS-PAGE, transferred onto polyvinylidene fluoride (PVDF) membranes (Immobilon-P, Millipore), and detected with primary and secondary antibodies listed in Additional file
1: Table S2 using ECL (Advansta, Cat. K-12,045-D50) and ChampChemi910 (Beijing Sage Creation Science Co., Ltd.).
Histopathology of TA muscles
Pathological examinations were performed as described elsewhere with minor modifications [
22‐
25]. Briefly, TA muscles of mouse were snap-frozen in isopentane chilled with liquid nitrogen. Quadriceps muscles were sliced at 8 μm with a cryostat. Hematoxylin and eosin (HE) staining was done according to the standard procedures. To determine the central nuclei, muscle fiber size and frequency distribution, tissue slides were observed using Olympus BX53 microscope. The cross-sectional area of the myofibers and the number of myonuclei was calculated from two random view per muscle sample using ImageJ.
Transfection and luciferase assays
To make the luciferase vector harboring the Mbnl1 promoter (pMbnl1), the mouse genomic region of chr3:60,407,525 − 60,408,852 according to GRCm37/mm9 was chemically synthesized, inserted into pGL3-Enhancer Vector (pGL3E, Promega) between BmtI and XhoI restriction sites, and was confirmed by Sanger sequencing (Sangon Biotech). Plasmids were introduced into Stbl3 Competent Cell (KTSM110L) and propagated. To measure the transcriptional activity of pMbnl1, C2C12 myoblasts were grown to 95% confluency in DMEM with 10% FBS, and then changed into the differentiation medium containing 2% HS and various concentrations of calcitriol. The cells were transiently transfected with pMbnl1 or pGL3E using Lipofectamine 3000 (ThermoFisher) according to the manufacturer’s recommendations. Five days later, the luciferase assay was performed using the Dual Luciferase Reporter Assay kit (Vazyme, Cat. DL101-01). For normalization, pRL-CMV Renilla Luciferase Reporter Vector was co-transfected, and the firefly luciferase activities were normalized to the Renilla luciferase activity.
Discussion
DM1 is a rare, multisystem disorder without curative or disease-modifying treatment to slow or stop disease progression [
29]. Symptomatic and supportive treatment, preventive measures and clinical surveillance are the currently available options for DM1 patients [
30]. The upregulation of MBNL1 protein level is a promising therapeutic strategy against DM1. Previous studies indicated that MBNL1 is downregulated in DM1 models and patients, and the overexpression of MBNL1 is beneficial in murine disease models [
5,
12]. Various drugs and epigenetic approaches have been found to promote endogenous MBNL1 expression and ameliorate the disease phenotypes in different experimental models [
31‐
34]. In the current study, we identified that calcitriol (active form of vitamin D3) elevated MBNL1 expression in mouse myogenic cells and in skeletal muscles of HSA
LR mouse model via enhancing the
Mbnl1 promoter activity.
Vitamin D plays essential roles in skeletal muscle. Vitamin D positively influences the protein synthesis and increases the size of muscle cells, leading to increased muscle mass, strength and performance [
35,
36]. Meta-analyses also reported beneficial effects of vitamin D supplementation on muscle strength and function in healthy adults [
37,
38]. Accordingly, vitamin D deficiency leads to muscle weakness and muscle mass reduction [
39,
40]. Clinical studies also identified a correlation between serum 25(OH)D concentration and muscle strength and function in older adults [
41,
42]. Importantly, vitamin D deficiency has been found to correlate with the severity of the disease symptoms in DM1 patients [
15,
16]. In our study, the upregulation of MBNL1 by calcitriol seems to be beneficial in the DM1 model, since the abnormal splicing of MBNL1-regulated genes (
Clcn1,
Serca1, and
Nfix) was partially corrected, and the muscle pathology as well as the muscle weakness was ameliorated. These results suggest that calcitriol upregulates MBNL1 expression and improves muscle strength in HSA
LR mice model.
MBNL1 is a splicing factor which can promote opposite splicing patterns for different genes depending on pre-mRNA binding context and interacting proteins [
8,
43]. The strength of alternative exon exclusion or inclusion highly depends on the MBNL1 binding affinity, relative concentration and local RNA structure features [
44]. MBNL1 could bind to the alternative exon or the upstream intron, causing exon skipping. It could also bind to the end of the alternative exon or to the downstream intron, promoting exon inclusion. This regulated alternative splicing activity of MBNL1 could potentially explain the observed differential effects of elevated MBNL1 on the aberrant splicing of
Clcn1,
Nfix and
Serca1 in calcitriol treated HSA
LR mice.
MBNL1 sequestration by abnormally expanded CUG repeats is key to the clinical symptoms in DM1 [
8], but this multi-systemic disease has also been found to be related with many other factors, such as increased CELF [
45] or HNRNPA1 [
46] expression, and decreased DMPK, SIX5, and DMWD expression [
47]. In line with this notion, although calcitriol could significantly upregulate MBNL1 protein level in the DM1 mouse model to ~ 70% of WT, it could only partially rescue various phenotypes of the disease model. Therefore, it would be interesting in the future to search for more potent chemicals, with structures similar to calcitriol or not, with therapeutic potential for DM1.
The involvement of calcitriol in the regulation of promoter activity has been previously reported. In target tissues, calcitriol binds to vitamin D receptor (VDR) and retinoid X receptor (RXR) [
48,
49]. The calcitriol-VDR-RXR complex binds to vitamin D response element (VDRE) in the promoter region of calcitriol-target genes [
50]. This binding leads to the recruitment of enzymatic coregulatory complexes that shift the local chromatin structure, facilitate the epigenetic modification of histones and improve the local concentration of RNA polymerase II (RNA pol II), leading to the regulation of mRNA expression [
50]. In our study, we found that calcitriol activates
Mbnl1 promoter and increases MBNL1 expression. However, the exact molecular mechanisms still remain unclear. The multiple predicted MEF2 binding sites (
http://jaspar.genereg.net/) in the
Mbnl1 promoter region may be involved and awaits further studies [
51].
Conclusion
Taken together, we reported that calcitriol activates Mbnl1 promoter, increases the endogenous MBNL1 protein expression, and improves muscle strength and function in DM1 mouse model, suggesting calcitriol as a potential pharmacological option for DM1 patients.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit
http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (
http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.